Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity

As the one-year anniversary of Bristol-Myers Squibb Company’s $74bn acquisition of Celgene Corporation approaches, Scrip spoke with chief medical officer Samit Hirawat about the big pharma’s achievements during a challenging period in which the COVID-19 pandemic threatened to derail clinical trials and a national spotlight on racial inequality shined a light on the industry’s lack of diversity.

Key products, such as the PD-1 inhibitor Opdivo (nivolumab), delivered positive results in important studies and won new approvals since the BMS-Celgene merger closed in November. However, Bristol promised Celgene shareholders an additional payout if three key product candidates were approved by certain dates... Read more »


UNDERWRITERS AND PARTNERS

          

          

            
Author: Mandy Jackson

Source : https://xconomy.com/national/2020/10/02/bristol-myerss-hirawat-on-pipeline-progress-clinical-trial-diversity/


Date : 2020-10-02T18:12:38.000Z

Post a Comment

Previous Post Next Post